329 related articles for article (PubMed ID: 19564547)
21. Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
Ikeda Y; Nakamura T; Takano H; Kimura H; Obata JE; Takeda S; Hata A; Shido K; Mochizuki S; Yoshida Y
J Lab Clin Med; 2000 Apr; 135(4):353-9. PubMed ID: 10779052
[TBL] [Abstract][Full Text] [Related]
22. Temocapril prevents transition to diastolic heart failure in rats even if initiated after appearance of LV hypertrophy and diastolic dysfunction.
Sakata Y; Yamamoto K; Mano T; Nishikawa N; Yoshida J; Miwa T; Hori M; Masuyama T
Cardiovasc Res; 2003 Mar; 57(3):757-65. PubMed ID: 12618237
[TBL] [Abstract][Full Text] [Related]
23. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability.
Schäfer A; Fraccarollo D; Eigenthaler M; Tas P; Firnschild A; Frantz S; Ertl G; Bauersachs J
Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1071-7. PubMed ID: 15761193
[TBL] [Abstract][Full Text] [Related]
24. Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats.
Iwanaga Y; Kihara Y; Hasegawa K; Inagaki K; Yoneda T; Kaburagi S; Araki M; Sasayama S
Circulation; 1998 Nov; 98(19):2065-73. PubMed ID: 9808606
[TBL] [Abstract][Full Text] [Related]
25. Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat.
Garjani A; Andalib S; Biabani S; Soraya H; Doustar Y; Garjani A; Maleki-Dizaji N
Eur J Pharmacol; 2011 Sep; 666(1-3):135-41. PubMed ID: 21570962
[TBL] [Abstract][Full Text] [Related]
26. Rosuvastatin changes cytokine expressions in ischemic territory and preserves heart function after acute myocardial infarction in rats.
Hu X; Sun A; Xie X; Huang Z; Jia J; Yao R; Ge J
J Cardiovasc Pharmacol Ther; 2013 Mar; 18(2):162-76. PubMed ID: 23139358
[TBL] [Abstract][Full Text] [Related]
27. The therapeutic effect of rosuvastatin on cardiac remodelling from hypertrophy to fibrosis during the end-stage hypertension in rats.
Zhang WB; Du QJ; Li H; Sun AJ; Qiu ZH; Wu CN; Zhao G; Gong H; Hu K; Zou YZ; Ge JB
J Cell Mol Med; 2012 Sep; 16(9):2227-37. PubMed ID: 22288611
[TBL] [Abstract][Full Text] [Related]
28. Rosuvastatin-attenuated heart failure in aged spontaneously hypertensive rats via PKCα/β2 signal pathway.
Qiu Z; Zhang W; Fan F; Li H; Wu C; Ye Y; Du Q; Li Z; Hu X; Zhao G; Sun A; Bao Z; Ge J
J Cell Mol Med; 2012 Dec; 16(12):3052-61. PubMed ID: 22970977
[TBL] [Abstract][Full Text] [Related]
29. [Effects of losartan, ramipril and their combination on left ventricular remodeling and function in spontaneous hypertensive rats].
Xu R; Zhang Y; Zhang M; Li XC; Cai H; Chen WQ; Zhu H; Ge ZM; Zhang W
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3199-204. PubMed ID: 16405840
[TBL] [Abstract][Full Text] [Related]
30. Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats.
Sun X; Ku DD
Am J Physiol Heart Circ Physiol; 2008 Feb; 294(2):H801-9. PubMed ID: 18055512
[TBL] [Abstract][Full Text] [Related]
31. Waon therapy attenuates cardiac hypertrophy and promotes myocardial capillary growth in hypertensive rats: a comparative study with fluvastatin.
Ihori H; Nozawa T; Sobajima M; Shida T; Fukui Y; Fujii N; Inoue H
Heart Vessels; 2016 Aug; 31(8):1361-9. PubMed ID: 26686369
[TBL] [Abstract][Full Text] [Related]
32. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial.
Ghio S; Scelsi L; Latini R; Masson S; Eleuteri E; Palvarini M; Vriz O; Pasotti M; Gorini M; Marchioli R; Maggioni A; Tavazzi L;
Eur J Heart Fail; 2010 Dec; 12(12):1345-53. PubMed ID: 20952767
[TBL] [Abstract][Full Text] [Related]
33. HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome.
Hermida N; Markl A; Hamelet J; Van Assche T; Vanderper A; Herijgers P; van Bilsen M; Hilfiker-Kleiner D; Noppe G; Beauloye C; Horman S; Balligand JL
Cardiovasc Res; 2013 Jul; 99(1):44-54. PubMed ID: 23542580
[TBL] [Abstract][Full Text] [Related]
34. Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure.
Zacà V; Rastogi S; Imai M; Wang M; Sharov VG; Jiang A; Goldstein S; Sabbah HN
J Am Coll Cardiol; 2007 Aug; 50(6):551-7. PubMed ID: 17678740
[TBL] [Abstract][Full Text] [Related]
35. Rosuvastatin prevents pressure overload‑induced myocardial hypertrophy via inactivation of the Akt, ERK1/2 and GATA4 signaling pathways in rats.
Xu X; Zhang L; Liang J
Mol Med Rep; 2013 Aug; 8(2):385-92. PubMed ID: 23799547
[TBL] [Abstract][Full Text] [Related]
36. Long-term administration of rosuvastatin prevents contractile and electrical remodelling of diabetic rat heart.
Ozturk N; Yaras N; Ozmen A; Ozdemir S
J Bioenerg Biomembr; 2013 Aug; 45(4):343-52. PubMed ID: 23640692
[TBL] [Abstract][Full Text] [Related]
37. Beneficial effect of rosuvastatin on cardiac dysfunction is associated with alterations in calcium-regulatory proteins.
Yang Y; Mou Y; Hu SJ; Fu M
Eur J Heart Fail; 2009 Jan; 11(1):6-13. PubMed ID: 19147451
[TBL] [Abstract][Full Text] [Related]
38. Rosuvastatin inhibits TGF-beta1 expression and alleviates myocardial fibrosis in diabetic rats.
Ma YX; Li WH; Xie Q
Pharmazie; 2013 May; 68(5):355-8. PubMed ID: 23802433
[TBL] [Abstract][Full Text] [Related]
39. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.
Krum H; Ashton E; Reid C; Kalff V; Rogers J; Amarena J; Singh B; Tonkin A
J Card Fail; 2007 Feb; 13(1):1-7. PubMed ID: 17338996
[TBL] [Abstract][Full Text] [Related]
40. Effects of HMG-CoA reductase inhibitor on experimental autoimmune myocarditis.
Liu X; Li B; Wang W; Zhang C; Zhang M; Zhang Y; Xia Y; Dong Z; Guo Y; An F
Cardiovasc Drugs Ther; 2012 Apr; 26(2):121-30. PubMed ID: 22382902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
